RAPT Therapeutics (RAPT) EBIAT (2020 - 2023)
Historic EBIAT for Therapeutics (RAPT) over the last 4 years, with Q4 2023 value amounting to -$30.9 million.
- Therapeutics' EBIAT fell 3453.88% to -$30.9 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$116.8 million, marking a year-over-year decrease of 3931.63%. This contributed to the annual value of -$116.8 million for FY2023, which is 3931.63% down from last year.
- Per Therapeutics' latest filing, its EBIAT stood at -$30.9 million for Q4 2023, which was down 3453.88% from -$31.4 million recorded in Q3 2023.
- In the past 5 years, Therapeutics' EBIAT ranged from a high of -$12.4 million in Q2 2020 and a low of -$31.4 million during Q3 2023
- Its 4-year average for EBIAT is -$20.2 million, with a median of -$18.9 million in 2021.
- As far as peak fluctuations go, Therapeutics' EBIAT crashed by 1385.45% in 2022, and later crashed by 4773.25% in 2023.
- Therapeutics' EBIAT (Quarter) stood at -$12.7 million in 2020, then crashed by 40.79% to -$17.9 million in 2021, then fell by 28.01% to -$23.0 million in 2022, then plummeted by 34.54% to -$30.9 million in 2023.
- Its EBIAT stands at -$30.9 million for Q4 2023, versus -$31.4 million for Q3 2023 and -$25.3 million for Q2 2023.